Krystal Biotech (KRYS) Finished Goods (2023 - 2026)

Krystal Biotech has disclosed Finished Goods across 4 years of filings, most recently posting $12.4 million for Q1 2026.

• Finished Goods for Q1 2026 came in at $12.4 million, up 109.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.4 million (up 109.53% YoY), and the FY2025 annual result was $9.3 million, up 338.05% from the prior year.
• Finished Goods came in at $12.4 million for Q1 2026 at Krystal Biotech, up from $9.3 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $12.4 million in Q1 2026 to a low of $161000.0 in Q1 2024.
• The 4-year median for Finished Goods is $2.7 million (2024), against an average of $4.4 million.
• Peak annual rise in Finished Goods reached 3563.35% in 2025, while the deepest fall reached 4.03% in 2025.
• Krystal Biotech's Finished Goods stood at $627000.0 in 2023, then soared by 239.07% to $2.1 million in 2024, then jumped by 338.05% to $9.3 million in 2025, then jumped by 32.7% to $12.4 million in 2026.
• The last three Finished Goods figures came in at $12.4 million (Q1 2026), $9.3 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.